Indo Borax & Chemicals Ltd (INDOBORAX)

Chemicals · Chemicals · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹514.3 ↑ 122.64% (1Y)

🎯 Key Takeaways

Indo Borax & Chemicals Ltd is transitioning from a mature boron chemicals producer to a diversified specialty chemicals player through its acquisition of Kronox Lab Sciences, while simultaneously strengthening its core business with strong profitability growth and strategic consolidation. The company is in a phase of active expansion, leveraging operational efficiency gains and targeted inorganic growth to drive future earnings momentum.
Revenue grew 11.7% QoQ to ₹70 in Q1FY27.
⚠️ Integration risk from the Kronox acquisition: Management's ability to successfully integrate Kronox and achieve synergies within the tight three-month

Market Cap

₹1,650

P/E Ratio

29.3

P/B Ratio

4.27

ROE

14.6%

ROCE

19.2%

Debt/Equity

0.00

Div Yield

7.78%

Promoter

38.4%

✨ Ask AI About INDOBORAX 📊 Interactive Charts

📖 The Story

Indo Borax & Chemicals Ltd is transitioning from a mature boron chemicals producer to a diversified specialty chemicals player through its acquisition of Kronox Lab Sciences, while simultaneously strengthening its core business with strong profitability growth and strategic consolidation. The company is in a phase of active expansion, leveraging operational efficiency gains and targeted inorganic growth to drive future earnings momentum.

📰 What's Happening

Management has executed a multi-pronged strategy in recent quarters: first, the board approved the amalgamation of its subsidiary lndoborax Infrastructure Private Ltd with the parent entity (BSE filing 2026-08-10), a move framed as enhancing operational synergy and growth momentum. Second, it announced a definitive agreement to acquire 64.26% of Kronox Lab Sciences at ₹103.22 per share, triggering a mandatory open offer for an additional 25.79% stake at ₹157.27 per share (BSE filings 2026-08-20), aiming to diversify into specialty fine chemicals with completion targeted within three months. Third, shareholders are being asked to approve a special resolution to borrow up to ₹400 crores via e-voting (BSE filing 2026-08-11), directly tied to funding these expansion initiatives. Management consistently highlighted sustained growth momentum and capacity utilisation in its core boron-based chemicals business during the Q1FY27 results announcement (BSE filing 2026-08-10).

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	58	41	63	70
Operating Profit	10	8	12	19
OPM %	16.7%	19.1%	19.4%	27.7%
Net Profit	16	9	15	16
EPS	₹5.07	₹2.89	₹4.53	₹5.07

The company's financial trajectory shows accelerating profitability and operational efficiency, with consolidated net profit surging 59.31% YoY to Rs 16.25 crore in Q1FY27 (BSE filing 2026-08-10), driven by a 31.34% rise in operating income to Rs 70.36 crore and significant margin expansion — EBITDA margin improved 530 bps to 28.1% and PAT margin rose 430 bps to 22.3%. This profitability surge occurred alongside rising revenue trends, with quarterly revenue growing from Rs 41 crore in Dec 2025 to Rs 58 crore in Sep 2025, Rs 63 crore in Mar 2026, and Rs 70 crore in Jun 2026, indicating consistent top-line expansion. The improvement in margins and profitability appears directly linked to management's highlighted focus on operational efficiencies and sustained demand in its core boron-based chemicals business, forming the financial foundation for its expansion strategy.

🔮 Management Outlook & What's Next

Management maintains an optimistic outlook, explicitly stating expectations to 'sustain growth momentum' moving forward (BSE filing 2026-08-10), underpinned by strong demand in its core boron chemicals business and the strategic rationale for diversification through the Kronox acquisition. While no detailed forward guidance on revenue or margins was provided in the latest filing, the company emphasized the 'robust demand' and 'improved operational efficiencies' as enduring drivers, suggesting confidence in continued outperformance in its core markets. The upcoming earnings call on September 2, 2026 (BSE filing 2026-08-27), will likely provide further clarity on how the newly approved borrowing capacity and integration of Kronox are expected to contribute to future growth trajectories.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	3	3	3	3
Reserves	312	332	358	383
Borrowings	10	0	0	0
Total Liabilities	343	357	384	405
Fixed Assets	98	101	94	9
Investments	23	57	64	248
Total Assets	343	357	384	405

The balance sheet reflects a pristine financial position with zero borrowings as of March 2026 (BSE filing data), providing significant financial flexibility to fund the ₹400 crore borrowing program and the Kronox acquisition without leverage constraints. Equity and reserves have steadily grown from ₹332 crore in March 2025 to ₹383 crore in March 2026, indicating retained earnings and capital accumulation. The absence of debt combined with strong operating cash flows (₹87 crore in March 2026) suggests management is prioritizing internal funding and strategic debt for growth rather than deleveraging, positioning the company to execute its expansion without diluting equity or straining liquidity.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2026
Operating	+87
Investing	-77
Financing	-3
Net Cash Flow	+7

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	50.8%	50.8%	30.8%	38.4%
FII	0.5%	0.2%	0.5%	0.1%
DII	0.0%	0.0%	2.2%	0.0%
Public	31.5%	32.0%	30.8%	28.0%
# Shareholders	22,387	21,091	20,466	20,592

Shareholding patterns reveal a concerning trend of promoter dilution, with promoter stake falling sharply from 50.8% in Q3FY26 to 30.8% in Q4FY26 and further to 38.41% in Q1FY27 (BSE shareholding data), while institutional ownership remains negligible (FII: 0.13%, DII: 0.04% in Q1FY27). The decline in promoter holding appears directly linked to the proposed acquisition of Kronox, where the open offer mechanism requires selling shareholders to exit their stake, potentially triggering further promoter reduction if they choose to participate in the offer. The rising number of shareholders (20,592 in Q1FY27 vs 22,387 in Q2FY26) suggests retail interest is growing, but the lack of institutional accumulation raises questions about broader market confidence despite strong financials.

⚖️ Peer Comparison — Chemicals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
PIDILITIND	1.67 L Cr	63.2	33.4%	24.7%	0.01
SRF	76,535	35.4	15.6%	15.4%	0.36
LINDEINDIA	54,418	99.6	17.5%	12.8%	0.00
FLUOROCHEM	52,063	85.1	9.6%	7.7%	0.34
NAVINFLUOR	44,292	56.0	22.2%	19.9%	0.31
GODREJIND	38,842	33.0	9.2%	19.8%	4.57
HSCL	34,339	42.7	20.7%	17.1%	0.16
DEEPAKNTR	24,328	31.1	15.3%	13.4%	0.26
AETHER	22,349	94.8	13.8%	10.6%	0.08
AARTIIND	19,030	35.8	9.2%	9.5%	0.68

🔗 Peer Stock Analyses

PIDILITIND SRF LINDEINDIA FLUOROCHEM NAVINFLUOR

⚠️ Risk Factors

1. Integration risk from the Kronox acquisition: Management's ability to successfully integrate Kronox and achieve synergies within the tight three-month window post-announcement is uncertain, with mandatory open offer creating potential shareholder resistance or dilution. 2. Capital allocation pressure: The proposed ₹400 crore borrowing authorization, coupled with the open offer, may strain financial flexibility if operational performance does not translate into sustained cash flow generation. 3. Promoter stake erosion: The sharp decline in promoter holding (from 50.8% to 30.8%) signals potential misalignment of interests and could undermine investor confidence if perceived as a lack of confidence in long-term prospects. 4. Market-specific demand volatility: Growth is heavily reliant on boron-based chemicals, which are cyclical and sensitive to downstream industrial demand in glass, ceramics, and detergents, with no explicit diversification of end-market exposure disclosed.

📋 Recent Filings

🧠 Analyst's Read

Indo Borax & Chemicals is executing a clear transformation strategy through strategic acquisitions and operational efficiency gains, supported by strong profitability trends and a clean balance sheet. However, the success of its diversification into specialty chemicals via the Kronox deal and the implications of promoter dilution remain key watchpoints for investors ahead of the earnings call and open offer outcome.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on INDOBORAX

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when INDOBORAX files new disclosures

Track INDOBORAX filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track INDOBORAX — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd